Skip to main content
KURA
NASDAQ Life Sciences

Kura Q3: KOMZIFTI Revenue Up 53% to $13.9M; Darlifarnib FDA Alignment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$7.45
Mkt Cap
$673.432M
52W Low
$6.75
52W High
$13.9
52W Position info
10% above low
Off High info
46% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

KURA is trading near its 52-week low of $6.75 (10% above the low).

Summary

Kura's KOMZIFTI sales grew 53% sequentially to $13.9 million in Q3 2026, and the company secured FDA alignment on a ~40-patient registrational study of darlifarnib in HRAS-mutant salivary gland cancer. With $492.1 million in cash and up to $300 million of Oberland Capital capacity, management says funding extends beyond the 2028 KOMET-017 topline.


Key Events · Earnings and Guidance · KURA

  • KOMZIFTI Revenue Grows 53% Sequentially

    Q3 2026 net product revenue was $13.9 million versus $9.1 million in Q2 2026, with roughly 150 new patient starts (up 30%) and more than 420 total prescriptions (up 65%).

  • Darlifarnib Registrational Path Aligned With FDA

    FDA alignment reached on a single-arm monotherapy registrational study of about 40 HRAS-mutant salivary gland cancer patients, with initiation targeted for 1H 2027.

  • Cash Funds Operations Past 2028 Readout

    $492.1 million in cash, cash equivalents and short-term investments at September 30, 2026, plus $180 million in anticipated Kyowa Kirin milestone payments and up to $300 million of conditional Oberland Capital capacity, is expected to fund operations beyond KOMET-017 topline in 2028.

  • Q3 Net Loss $70.2 Million

    R&D was $66.9 million and SG&A $30.2 million, producing a $70.2 million net loss versus $74.1 million a year earlier; 2026 collaboration revenue guidance was updated to $40-45 million.


Analysis · KURA · Life Sciences

KOMZIFTI's second full quarter of sales reached $13.9 million, up 53% from $9.1 million in Q2, while new patient starts rose 30% and total prescriptions climbed 65% — evidence the launch is compounding rather than plateauing, and Kura still holds a majority of new patient starts in the R/R NPM1-mutant AML menin inhibitor class. Separately, the company reached FDA alignment on a roughly 40-patient single-arm registrational study of darlifarnib in HRAS-mutant salivary gland cancer, a potential second approval with study start targeted for the first half of 2027. Cash of $492.1 million, plus $180 million in anticipated Kyowa Kirin milestone payments and up to $300 million of conditional Oberland Capital capacity, is expected to fund operations beyond the KOMET-017 frontline topline readout in 2028 — so the equity does not need to be sold to reach that catalyst. The offset is cost: the Q3 net loss was $70.2 million and 2026 collaboration revenue guidance was trimmed to $40-45 million, reflecting accounting recognition rather than cash timing.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KURA was trading at $7.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $673.4M. The 52-week trading range was $6.75 to $13.90. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KURA - Latest Insights

KURA
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.29
Real-time Price: $7.86 info
Change: +$0.570 (+8%) info
Market Cap: $699.23M info
KURA
Nov 10, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.20
Real-time Price: $7.86 info
Change: +$0.660 (+9%) info
Market Cap: $699.23M info
KURA
Nov 10, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.45
Real-time Price: $7.86 info
Change: +$0.410 (+6%) info
Market Cap: $699.23M info
KURA
Sep 29, 2026, 5:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.70
Real-time Price: $7.86 info
Change: -$2.84 (-27%) info
Market Cap: $699.23M info
KURA
Sep 09, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.64
Real-time Price: $7.86 info
Change: -$4.78 (-38%) info
Market Cap: $699.23M info